Cardiac binding in experimental heart failure.
BACKGROUND
Cardiomyoplasty is a potential therapy for heart failure. Its benefits are attributed to systolic augmentation (dynamic cardiomyoplasty) and prevention of cardiac dilatation (static cardiomyoplasty). To evaluate the static component, we used an artificial membrane for cardiac binding in a canine model of heart failure.


METHODS
Intracoronary doxorubicin was administered weekly for 4 weeks to induce heart failure in 10 dogs, each of which was assigned to one of two treatment groups: (1) no treatment, or (2) cardiac binding. Hemodynamic data were obtained at operation and at 7 weeks after operation. Echocardiography was performed weekly.


RESULTS
Left ventricular end-diastolic pressure and diameter, and right ventricular end-diastolic diameter increased in group 1 (from 9.6 +/- 6.1 to 19.6 +/- 2.3 mm Hg, p = 0.009; from 3.9 +/- 0.4 to 5 +/- 0.3 cm, p = 0.0013; and from 1.6 +/- 0.2 to 1.9 +/- 0.3 cm, p = 0.0036, respectively). Ejection fraction fell in group 1 from 0.60 +/- 0.10 to 0.40 +/- 0.04 (p = 0.0009) and in group 2 from 0.56 +/- 0.02 to 0.40 +/- 0.04 (p = 0.0001), but the difference between groups was not significant.


CONCLUSIONS
Cardiac binding reduces the ventricular dilatation associated with heart failure without exacerbating left ventricular dysfunction.
Vaynblat
M
M
Division of Cardiothoracic Surgery, State University of New York-Health Science Center at Brooklyn 11203, USA.
Chiavarelli
M
M
Shah
H R
HR
Ramdev
G
G
Aron
M
M
Zisbrod
Z
Z
Cunningham
J N
JN
D000818:Animals; D000903:Antibiotics, Antineoplastic; D002303:Cardiac Output, Low / Q000139:chemically induced / Q000503:physiopathology / Q000601:surgery*; D018421:Cardiomyoplasty / Q000379:methods*; D004195:Disease Models, Animal; D004285:Dogs; D004317:Doxorubicin; D006439:Hemodynamics; D008297:Male; D008567:Membranes, Artificial; D013997:Time Factors; D016277:Ventricular Function, Left
D000903:Antibiotics, Antineoplastic; D008567:Membranes, Artificial; D004317:Doxorubicin